CF PharmTech, Inc.
長風藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2652)

POLL RESULTS OF 2025 FIRST EXTRAORDINARY GENERAL MEETING

The board (the "**Board**") of directors (the "**Directors**") of CF PharmTech, Inc. (長風藥業股份有限公司) (the "**Company**") is pleased to announce that the 2025 first extraordinary general meeting (the "**EGM**") was held at No. 16, Hucundang Road, Xiangcheng Economic Development District, Suzhou, Jiangsu, PRC, at 1 p.m. on Tuesday, December 16, 2025.

Reference is made to the Company's circular dated November 26, 2025 (the "**Circular**"). Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

As at the date of the EGM, the total number of the issued Shares of the Company was 411,978,387 Shares, comprising 109,754,801 domestic shares and 302,223,586 H Shares. No treasury Shares were held by the Company. As such, holders of 411,978,387 Shares (or authorized proxies) were entitled to attend and vote on the resolutions proposed at the EGM. There were no Shares entitling the Shareholders to attend and vote only against the resolutions at the EGM.

ATTENDANCE AT THE EGM

The Board comprises 11 members, all of whom attended the EGM in person or by electronic.

The Shareholders or authorized proxies of the Shareholders attending the EGM held an aggregate of 200,275,550 Shares with voting rights in aggregate, representing approximately 48.61% of the total issued Shares of the Company. Voting at the EGM was conducted by way of poll. The EGM was convened and held in accordance with the applicable PRC laws and regulations, the Listing Rules and the Articles of Association.

To the best knowledge, information and belief of the Company: (i) there were no restrictions on any Shareholders to cast votes on any of the proposed resolutions at the EGM; (ii) no Shareholder was required under the Listing Rules to abstain from voting on any of the proposed resolutions at the EGM; (iii) there were no Shares entitling the holders to attend and abstain from voting in favor of any of the proposed resolutions at the EGM as required by Rule 13.40 of the Listing Rules; and (iv) no party stated any intention in the Circular to vote against or abstain from voting on any of the proposed resolutions.

Computershare Hong Kong Investor Services Limited (the H share registrar of the Company) acted as the scrutineers for the vote-taking at the EGM.

POLL RESULTS OF THE EGM

All resolutions proposed at the EGM were voted by registered poll. The poll results were as follows:

Special resolutions		Number of votes (Percentage of the total voting Shares at the EGM)			Passed by Shareholders
		For	Against	Abstain	
1.	To consider and approve the Share Repurchase Mandate, with the details as set out in the Circular.	200,275,550 (100%)	– (–)	– (–)	Yes
2.	To consider and approve the proposed adoption of the H Share Award Scheme.	200,275,550 (100%)	– (–)	– (–)	Yes
3.	To consider and approve proposed authorization to the Board and/or authorized person to handle matters relating to the H Share Award Scheme.	200,275,550 (100%)	– (–)	– (–)	Yes

As more than two thirds of the votes from the Shareholders (including their proxies) attending the EGM were cast in favor of all resolutions above, such resolutions duly passed as special resolutions at the EGM.

By order of the Board
CF PharmTech, Inc.
長風藥業股份有限公司
Dr. LIANG Bill Wenqing
Chairperson, Executive Director and Chief Executive Officer

Hong Kong, December 16, 2025

As at the date of this announcement, the Board comprises Dr. LIANG Bill Wenqing, Dr. LI LI BOVET, Dr. LI Qi and Ms. ZHU Yuyu as executive Directors, Mr. CHEN Penghui, Mr. CAI Lei and Dr. YI Hua as non-executive Directors, and Dr. JIN Jian, Ms. WANG Lijuan, Mr. WEI Shirong and Mr. IP Wang Hoi as independent non-executive Directors.